Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
life sciences
national blog main
national top stories
new york blog main
5
×
boston blog main
boston top stories
new york top stories
san francisco blog main
fda
san diego blog main
san diego top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
eli lilly
genentech
ipo
national
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
acetylon pharmaceuticals
advaxis
aimmune therapeutics
alder biopharmaceutical
alder biopharmaceuticals
alexander hardy
allergan
amarin
ambys medicines
What
big
5
×
make
medicine
new
abuzz
acquire
ago
agreed
aiming
amarin
ambys
approval
arguments
billion
bio
biotech
bosley's
bosley’s
bridge
broad
bucks
cas
ceo
class
clinical
commercialized
community
companies
competitors
confidence
control
crime
crispr
deadly
deal
debuted
decades
deeper
departure
didn’t
Language
Current search:
big
×
biotech
×
" new york blog main "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine